Ironwood Pharmaceuticals reports Q2 revenues of $65.1M — 4 insights

Ironwood Pharmaceuticals reported second quarter fiscal year 2017 revenues of $65.1 billion, Nasdaq reports.

Here's what you should know:

1. Despite a 19.7 percent year-over-year increase, the company's revenues were lower than Zacks' estimated $68.5 million.

2. Ironwood reported adjusted losses of $0.28 per share. The losses were higher than Zacks' estimated $0.23 per share.

3. Ironwood's key product Linzess generated $167.8 million in sales. As per an agreement, Ironwood splits Linzess sales with Allergan. Ironwood's net profits from Linzess amounted to $43.8 million.

4. Linzess prescriptions increased 15 percent in the second quarter, surpassing 750,000.

More articles on gastroenterology:
Nevada Supreme Court overturns 2nd-degree murder conviction against gastroenterologist linked to Las Vegas hepatitis C outbreak — 4 insights
Olympus to pay $6.6M in duodenoscope-related damages — 6 key takeaways
Renewed interest in gastroparesis research brings cure into focus — 4 key notes

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months